ALTIMMUNE, INC. Debt Securities, Available-for-sale, Amortized Cost
ALTIMMUNE, INC. (ALT) had Debt Securities, Available-for-sale, Amortized Cost of $456.52 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $456.52M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $234.12M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $229.58M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $149.52M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $456.52M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $234.12M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $229.58M 10-Q · filed 2026-05-13 |
| 2025-09-30 | $149.52M 10-Q · filed 2025-11-06 |
| 2025-03-31 | $100.69M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $94.90M 10-K · filed 2026-03-06 |
| 2024-09-30 | $107.71M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $107.93M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $103.17M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $62.66M 10-K · filed 2025-02-27 |
| 2023-09-30 | $54.01M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $57.74M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $61.10M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $73.97M 10-K · filed 2024-03-27 |
| 2022-09-30 | $74.63M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $49.02M 10-Q · filed 2022-08-11 |
| 2021-09-30 | $25.02M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $43.72M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $76.57M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $100.01M 10-K · filed 2022-03-15 |
| 2020-09-30 | $63.28M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $15.48M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $21.66M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $28.26M 10-K · filed 2021-02-25 |
| 2019-09-30 | $28.21M 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |